Drug Channels

NOVEMBER 23, 2021

Recent posts have covered: outcomes-based contracts, copay accumulators, hospitals’ drug profits, biosimilar interchangeability, managed Medicaid, DSCSA, CVS Health’s networks, unintended consequences of congressional drug pricing legislation, Walmart and TRICARE, McKesson’s European retreat, and more. to 1:30 p.m.

Drug Pricing 74

Drug Pricing Biosimilars Hospitals 74

Drug Channels

NOVEMBER 22, 2021

Recent posts have covered: outcomes-based contracts, copay accumulators, hospitals’ drug profits, biosimilar interchangeability, managed Medicaid, DSCSA, CVS Health’s networks, unintended consequences of congressional drug pricing legislation, Walmart and TRICARE, McKesson’s European retreat, and more. to 1:30 p.m.

Specialty Pharmacies 75

Specialty Pharmacies Drug Pricing Biosimilars Hospitals 75

pharmaphorum

SEPTEMBER 28, 2020

pharmaphorum’s Behavioural insights into haem/onc clinical decision making webinar, in association with Medscape, showed that this can negatively impact physicians’ confidence as they try and keep on top of information about an array of treatment options. Data from the US cited during the webinar showed a five-year survival rate of 34.2%

Biosimilars 105

Biosimilars Hospitals 105

Drug Channels

NOVEMBER 24, 2020

My recent tweets have highlighted: doctors against step therapy, distribution of COVID-19 therapies, biosimilar savings, copay accumulator data, prospects for smaller PBMs, the new transparency rule, specialty pharmacy profit metrics, the future of oncology practices, and an update on Diplomat founder Phil Hagerman. to 1:15 p.m.

Specialty Pharmacies 52

Specialty Pharmacies Biosimilars Hospitals 52

Drug Channels

NOVEMBER 23, 2021

Recent posts have covered: outcomes-based contracts, copay accumulators, hospitals’ drug profits, biosimilar interchangeability, managed Medicaid, DSCSA, CVS Health’s networks, unintended consequences of congressional drug pricing legislation, Walmart and TRICARE, McKesson’s European retreat, and more. to 1:30 p.m.

Specialty Pharmacies 40

Specialty Pharmacies Drug Pricing Biosimilars Hospitals 40

PharmaState Academy

MAY 1, 2023

In the coming age of biopharmaceuticals and biosimilars, every patient will have different needs, especially young patients with life-style disease problems. I love the way Ogilvy sends automated reminders for their webinars! See the mad rush to ‘meet their near-and-dear ones’ in hospitals during the visitor-hours!

Department of Veterans Affairs 52

Department of Veterans Affairs Communication Hospitals Biosimilars 52

FDA Law Blog: Biosimilars

JUNE 21, 2023

What processes and medical procedures, including diagnostics, do you believe would be ideal for transitioning from a hospital and/or healthcare setting to non-clinical care settings, for example, home use or school/work use? What medical technologies could be ideal to transition to use in non-clinical settings?

Documentation 45

Documentation Hospitals 45

FDA Law Blog: Biosimilars

SEPTEMBER 12, 2023

More than 40 registrants — primarily hospitals and pharmacies — have paid significant civil penalties of up to $5,000,000 to settle allegations they failed to report controlled substance thefts or significant losses to the Drug Enforcement Administration (DEA). The risks to hospitals and pharmacies are multi-faceted and growing.

Controlled Substances 49

Controlled Substances Hospitals 49

FDA Law Blog: Biosimilars

SEPTEMBER 26, 2023

More than 40 registrants — primarily hospitals and pharmacies — have paid significant civil penalties of up to $5,000,000 to settle allegations they failed to report controlled substance thefts or significant losses to the Drug Enforcement Administration (DEA). The risks to hospitals and pharmacies are multi-faceted and growing.

Controlled Substances 45

Controlled Substances Hospitals 45

Drug Channels

DECEMBER 1, 2020

Speaking of next year, Drug Channels Institute will host an exclusive live webinar, Drug Channels Outlook 2021 , on December 18, 2020, from 12:00 p.m. Below, I highlight six trends that will affect the U.S. drug wholesaling industry. I hope you enjoy this summary as we look toward the new year. to 1:15 p.m. d/b/a Drug Channels Institute.

Vaccines 40

Vaccines Biosimilars Hospitals 40